Navigation Links
Cell signaling discovery provides new hope for blood disorders
Date:2/16/2012

Walter and Eliza Hall Institute scientists have revealed new details about how cell signalling is controlled in the immune system, identifying in the process potential new therapeutic targets for treating severe blood disorders.

Dr Jeff Babon and Professor Nick Nicola, from the institute's Structural Biology and Cancer and Haematology divisions respectively, study interactions between internal cell signalling proteins called JAKs (Janus kinases) and SOCS (Suppressors of Cytokine Signalling).

Dr Babon said the proteins were essential for blood system maintenance and immune responses.

"JAK proteins are activated in response to blood cell hormones called cytokines and instruct immune cells to respond to infection and inflammation," Dr Babon said. "SOCS proteins were discovered at the institute in the early 2000s, and provide a necessary 'negative feedback' response that stops JAKs becoming overactive, which can lead to disease."

Dr Babon said mutations in one particular protein, JAK2, are strongly associated with the development of myeloproliferative diseases.

"When JAK2 is mutated, it tells cells to continually multiply. An excessive amount of blood cells of one type are produced, and the bone marrow is overrun, leading to problems with production of other cell types, and eventually bone marrow failure," Dr Babon said.

Myeloproliferative diseases, such as polycythemia vera and essential thrombocytopenia, are serious blood disorders in which an excessive number of blood cells accumulate in the bone marrow. They can be very severe and sometimes fatal, and may progress to acute leukaemias.

In a study published today in the journal Immunity, Dr Babon and Professor Nicola, with colleagues Dr James Murphy and Dr Nadia Kershaw, report on a key discovery about how the proteins JAK2 and SOCS3 interact. They hope the discovery will lead to new strategies for treating myeloproliferative diseases.

"SOCS3 is a key inhibitor of JAK2 proteins in blood and immune cells, but we didn't know exactly how the two proteins interacted to suppress JAK2 function," Dr Babon said. "We wanted to identify which site the SOCS3 protein bound to on the JAK2 protein to inhibit its action, and were surprised to find that SOCS3 binds to a unique site on JAK2 and directly inhibits the protein, rather than outcompeting other molecules."

Dr Babon said the finding could inspire a new class of therapeutic agents for treating myeloproliferative diseases.

"The SOCS3 binding site is a previously unknown part of the JAK2 protein which could be exploited as a drug target, with greater specificity than other drugs that are currently in clinical trials for inhibiting JAK2," he said.


'/>"/>
Contact: Liz Williams
williams@wehi.edu.au
61-405-279-095
Walter and Eliza Hall Institute
Source:Eurekalert

Related medicine news :

1. Plant flavonoid luteolin blocks cell signaling pathways in colon cancer cells
2. Cell signaling key to stopping growth and migration of brain cancer cells
3. Insulin signaling is distorted in pancreases of Type 2 diabetics
4. Unexpected signaling role for foul-smelling hydrogen sulfide in cell response to protein misfolding
5. New gene study of ADHD points to defects in brain signaling pathways
6. Unraveling the complex signaling that helps cells know when to grow, when to sit tight
7. How major signaling pathways are wired to our genome gives new insight into disease processes
8. Stem cells, signaling pathways identified in lung repair
9. Signaling molecule identified as essential for maintaining a balanced immune response
10. NYU researchers develop compound to block signaling of cancer-causing protein
11. Roadmap published for dynamic mapping of estrogen signaling in breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, ...
(Date:2/12/2016)... ... 2016 , ... As a former television executive, owner Tal Rabinowitz knows how ... to decompress, Rabinowitz found herself drawn to a casual meditation class while working at ... life, implementing a 20-minute-per-day meditation practice with her team. After her tenure at NBC, ...
(Date:2/12/2016)... ... 12, 2016 , ... Itopia, a leader in cloud services ... Intelligence Platform (CIP) into Cielo®, a discovery, migration and cloud orchestration engine. This ... small and medium business (SMB) clients. , In recent years, BI ...
(Date:2/12/2016)... Arlington, TX (PRWEB) , ... February 12, 2016 , ... ... Worth, and other communities across eastern Texas, is launching a cooperative charity drive with ... and families. , Serving more than 50,000 individuals and families in need, the Tarrant ...
(Date:2/12/2016)... ... ... Donor Network West, the organ procurement organization that heals lives through organ ... Regional Medical Center. Under the collaboration, the first of its kind, specific organ donors ... certain time frame for donor families for the recovery of organs. , Organ ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... -- Eli Lilly and Company (NYSE: LLY ) today announced ... vitamin regimen patent would not presently be infringed by Actavis ... , Italy and Spain ... dextrose solution.  --> --> ... held that Lilly,s patent would be indirectly infringed by Actavis ...
(Date:2/12/2016)... 2016  Apellis Pharmaceuticals, Inc., today announced ... Series D preferred stock financing, co-led by ... Group and venBio Global Strategic Fund, joining ... Investment, and Epidarex Capital. The proceeds of the ... clinical trials in the Company,s ongoing complement ...
(Date:2/11/2016)... , Feb. 11, 2016 The primary ... and future adoption patterns on the usage of liquid ... the following: - Timeframe of liquid biopsy ... ctDNA, cfDNA and Evs—by organization type - Sample inflow ... types: blood, saliva, stool, serum, and so on. - ...
Breaking Medicine Technology: